---
figid: PMC6325856__12933_2019_806_Fig10_HTML
figtitle: The proposed cardioprotective mechanism of mAb A treatment in hearts following
  a myocardial infarction
organisms:
- NA
organisms_ner:
- Drosophila melanogaster
- Homo sapiens
pmcid: PMC6325856
filename: 12933_2019_806_Fig10_HTML.jpg
figlink: /pmc/articles/PMC6325856/figure/Fig10/
number: F10
caption: Schematic illustration of the proposed cardioprotective mechanism of mAb
  A treatment in hearts following a myocardial infarction. Glucagon receptor antagonism
  increases the insulin signalling pathway and the BCAA catabolic pathway, while inhibiting
  the mTOR pathway. IRS-1 insulin receptor substrate-1, Akt protein kinase B, GSK-3β
  glycogen synthase kinase-3 beta, mTOR mammalian target of rapamycin, P70S6K ribosomal
  protein S6 kinase, AS160 Akt substrate 160, GLUT4 glucose transporter 4, PDH pyruvate
  dehydrogenase, TAK1 transforming growth factor beta-activated kinase 1, p38 MAPK
  p38 mitogen-activated protein kinase, KLF15 Krüppel-like factor 15, BCATm mitochondrial
  branched chain aminotransferase, BCAA branched chain amino acids, TCA tricarboxylic
  acid, MPC mitochondrial pyruvate carrier. Red arrows indicate the cellular changes
  following mAb A treatment in post-MI heart
papertitle: Targeting the glucagon receptor improves cardiac function and enhances
  insulin sensitivity following a myocardial infarction.
reftext: Qutuba G. Karwi, et al. Cardiovasc Diabetol. 2019;18:1.
year: '2019'
doi: .na.character
journal_title: .na.character
journal_nlm_ta: .na.character
publisher_name: .na.character
keywords: .na.character
automl_pathway: 0.9681165
figid_alias: PMC6325856__F10
figtype: Figure
redirect_from: /figures/PMC6325856__F10
ndex: 01b6cb7b-decd-11ea-99da-0ac135e8bacf
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC6325856__12933_2019_806_Fig10_HTML.html
  '@type': Dataset
  description: Schematic illustration of the proposed cardioprotective mechanism of
    mAb A treatment in hearts following a myocardial infarction. Glucagon receptor
    antagonism increases the insulin signalling pathway and the BCAA catabolic pathway,
    while inhibiting the mTOR pathway. IRS-1 insulin receptor substrate-1, Akt protein
    kinase B, GSK-3β glycogen synthase kinase-3 beta, mTOR mammalian target of rapamycin,
    P70S6K ribosomal protein S6 kinase, AS160 Akt substrate 160, GLUT4 glucose transporter
    4, PDH pyruvate dehydrogenase, TAK1 transforming growth factor beta-activated
    kinase 1, p38 MAPK p38 mitogen-activated protein kinase, KLF15 Krüppel-like factor
    15, BCATm mitochondrial branched chain aminotransferase, BCAA branched chain amino
    acids, TCA tricarboxylic acid, MPC mitochondrial pyruvate carrier. Red arrows
    indicate the cellular changes following mAb A treatment in post-MI heart
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - mab
  - Tak1
  - Mtor
  - Tor
  - Akt
  - lic
  - p38b
  - Nurf-38
  - Ebp
  - AIMP2
  - p38a
  - Hrb87F
  - p38c
  - S6k
  - pyr
  - sgg
  - gskt
  - Ate1
  - Klf15
  - Pdh
  - Pdha
  - Pdf
  - Pdhb
  - Mpc1
  - Coa
  - ca
  - arm
  - CG1673
  - CycE
  - cyc
  - SLC2A4
  - MAP3K7
  - NR2C2
  - MTOR
  - AKT1
  - AKT2
  - AKT3
  - TBC1D4
  - CRK
  - MAPK14
  - MAPK1
  - GRAP2
  - AHSA1
  - POLDIP2
  - MAPK11
  - MAPK12
  - MAPK13
  - RPS6KB1
  - RPS6KB2
  - GSK3B
  - ATM
  - KLF15
  - PDP1
  - DLAT
  - DLD
  - PDHA1
  - PDHA2
  - PDHB
  - PDHX
  - ARID4B
  - Glucose
  - Ir
  - Pyruvate
  - TCA
  - Pyruvate Acetyl
  - Acetyl CoA
  - Hypertrophy
  - Glucose oxidation
  - Glucose I Glucose
---
